| 侯鹏飞,刘展会,张 睿,马康孝,程文佳,郭世文.辛伐他汀对大鼠蛛网膜下腔出血后脑血管痉挛的治疗效果研究[J].现代生物医学进展英文版,2017,17(5):815-819. |
| 辛伐他汀对大鼠蛛网膜下腔出血后脑血管痉挛的治疗效果研究 |
| Efficacy of Simvastatin in the Treatment of Rats with Cerebral Vasospasm after Subarachnoid Hemorrhage |
| Received:September 06, 2016 Revised:September 28, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.05.004 |
| 中文关键词: 辛伐他汀 蛛网膜下腔出血 脑血管痉挛 缺血性神经功能障碍 |
| 英文关键词: Simvastatin Subarachnoid hemorrhage Cerebral vasospasm Ischemic nerve dysfunction |
| 基金项目:陕西省自然科学基金项目（D201234）；西安市卫生和计划生育委员会科技项目（J201602035） |
|
| Hits: 492 |
| Download times: 229 |
| 中文摘要: |
| 摘要 目的：观察辛伐他汀对大鼠蛛网膜下腔出血后脑血管痉挛的治疗效果并探讨其可能机制。方法：将48只健康Wistar大鼠随机分为正常对照组、模型组、辛伐他汀组，每组各16只。模型组以及辛伐他汀组给予枕大池注入自体动脉血法以建立大鼠蛛网膜下腔出血后脑血管痉挛的动物模型，辛伐他汀组于第1次注血后开始给予辛伐他汀皮下注射，其余两组给予等体积生理盐水皮下注射。比较各组大鼠情况、组织学检查结果、蛛网膜下腔出血量评分、神经功能缺损评分、血管内径、血管舒张度、血管痉挛程度、eNOS以及TNF-α蛋白表达水平。结果：实验过程中，正常对照组无大鼠死亡，模型组大鼠死亡率为33.33%，辛伐他汀死亡率为6.67%，较模型组显著降低(P<0.05)。治疗后，与正常对照组相比，模型组及辛伐他汀组大鼠蛛网膜下腔出血量评分及TNF-α阳性表达率较高(P<0.05)，神经功能缺损评分、血管内径、D/T及eNOS阳性表达率较低(P<0.05)；与模型组相比，辛伐他汀组蛛网膜下腔出血量评分及TNF-α阳性表达率较低(P<0.05)，神经功能缺损评分、血管内径、D/T及eNOS阳性表达率较高(P<0.05)。结论：辛伐他汀可有效改善蛛网膜下腔出血后脑血管痉挛，这可能与其上调eNOS蛋白表达并下调TNF-α蛋白表达有关。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the efficacy of simvastatin on the treatment of cerebral vasospasm after subarachnoid hemor- rhage in rats. Methods: 48 healthy WISTAR rats were divided into normal control group, model control group and simvastatin group, with 16 rats in each group. The rats in the model control group and model control group were given intracisternal injection of autologous arterial blood to establish the rat animal model of cerebral vasospasm after subarachnoid hemorrhage, and the rats in the simvastatin group were given simvastatin after the first injection of blood, while the other two groups were given saline subcutaneous injection. Then the rats situations, histological examination results, subarachnoid haemorrhage amount grade score, neural function defect score, blood vessel diameter, blood vessels tension degree, vasospasm degree, eNOS and TNF-α protein expression levels of the three groups were ob- served and compared. Results: In the experiment, there was no death in the normal control group, there were five rats died in the model control group with the death rate of 33.33%, and there was a rat died in the simvastatin group with the death rate of 6.67%. After treat- ment, compared with the normal control group, the subarachnoid haemorrhage amount score were higher in the model control group and simvastatin group (P<0.05), and neural function defect score, blood vessel diameter and D/T were lower (P<0.05); Compared with model control group, the subarachnoid haemorrhage amount score was lower in the simvastatin group (P<0.05), and neural function defect scale, blood vessel diameter and D/T were higher (P<0.05). Compared with normal control group, eNOS positive expression rate in the model control group and simvastatin group were lower (P<0.05), and the TNF-α positive expression rate was higher (P<0.05); Compared with model control group, the eNOS positive expression rate was higher in the simvastatin group (P<0.05), and the TNF-α positive expression rate was lower (P<0.05). Conclusion: Simvastatin in the treatment of subarachnoid hemorrhage is safe and effective, which can increase the eNOS protein expression, decrease the TNF-α protein expression, reduce the incidence rate of ischemic neurological dysfunction and blood vessel spasm, and it is expect to provide new methods of intervention for clinical treatment. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
